Why Your Heart Skips a Beat During Exercise: The R33Q Mystery Solved

Let us discuss a specific genetic variant known as R33Q in calsequestrin 2, or CASQ2. This variant disrupts calcium control within heart cells and subsequently activates protein-degradation mechanisms. As we look at the data emerging from the Centro Nacional de Investigaciones Cardiovasculares Carlos III, or CNIC, a clear picture is forming regarding an inherited form of catecholaminergic polymorphic ventricular tachycardia, or CPVT. This condition is a life-threatening inherited arrhythmic disease that can cause loss of consciousness and even sudden death, primarily affecting children and young adults. The symptoms are particularly dangerous because arrhythmias often appear during exercise or emotional stress when the heart's activity increases significantly. A recent study published in the journal Circulation Research has identified a protein-degradation mechanism that contributes to the development of this form of CPVT. The findings point toward a possible therapeutic strategy based on inhibiting the enzyme calpain. This research was led by researchers at the CNIC, in collaboration with the University of Pavia and IRCCS Istituti Clinici Scientifici Maugeri in Italy. Researchers from the Spanish cardiovascular research network, or CIBERCV, also took part in this study.

From a clinical standpoint, understanding the molecular regulation of heart failure is critical. The study was led by Dr. Enrique Lara-Pezzi, who heads the Molecular Regulation of Heart Failure group at the CNIC. Collaborating with him were Dr. Silvia G. Priori of IRCCS Istituti Clinici Scientifici Maugeri and the University of Pavia. They examined a specific form of CPVT caused by a mutation in the gene encoding calsequestrin. This protein helps control calcium inside heart cells. Calcium is essential for the heart to contract in a coordinated way with every beat. Disruptions to its regulation can trigger the dangerous abnormal heart rhythms we see in CPVT patients. The study utilized a combination of proteomics techniques, experimental models, cellular and biochemical studies to uncover the underlying pathology. Their findings suggest that the problem does not end with the initial disruption of calcium handling. Instead, this abnormality activates various cellular degradation mechanisms that reduce the levels of essential proteins in the molecular complex responsible for regulating calcium release inside cardiomyocytes. One critical mechanism involves the calcium-dependent enzyme calpain.

The researchers demonstrated that calpain activity is increased in animals carrying the R33Q mutation. This enzyme directly targets triadin, a protein that helps stabilize the calcium-release machinery. The results reveal a previously unknown sequence of events. The degradation of triadin precedes the loss of mutant calsequestrin and actually contributes to its destabilization. This insight is vital because it shifts our understanding of the disease progression. It is not merely that the protein is broken; it is that the protein is actively being degraded and removed from the cellular environment. Pharmacological blockade of calpain appeared to restore several proteins of this machinery. This treatment improved calcium handling in heart cells and reduced the occurrence of ventricular arrhythmias in mice with the disease. The results were consistent and significant. Representative ECG recordings from mice with CPVT showed a clear difference between untreated and treated animals after administration of adrenaline to trigger arrhythmias. The treatment reduced the proportion of animals that developed sustained ventricular tachycardia.